

FIGURE 1

2/20

Diss. of CBZ-E from various waxes




FIGURE 2

3/20




FIGURE 3

4/20





FIGURE 4

5/20


Diss. of CBZ-E tablet (185mg, 80% CBZ-E)
("blocked", 35C)



—■— H15 —○— H37 —△— H175 —*— W31

FIGURE 5

6/20

TIME (h)
FIGURE 6

—□—	h5(%)
—●—	h15(%)
—■—	h37(%)
—○—	h175(%)
—■—	w31(%)




FIGURE 7

8/20




FIGURE 8

9/20




FIGURE 9

10/20

—□—	34C
—●—	35C
—■—	36C
—○—	37C
—■—	38C
—□—	40C

Diss. of CBZ-E "blocked" tab. with h15
at various temp.




FIGURE 10

11/20




FIGURE 11

12/20




FIGURE 12

13/20





FIGURE 13

14/20

09/743260



Time^{1/2} (h^{1/2})

FIGURE 14

15/20

CBZ-E Plasma levels
obtained after *i.v.* and oral administration to dogs (250 mg)




FIGURE 15

16/20

MHD Plasma levels
obtained after *i.v.* and oral administration to dogs (400 mg)




FIGURE 16

17/20

MHD Plasma levels
obtained after *i.v.* and oral administration to dogs (400 mg)




FIGURE 17

18/20

MHD Plasma levels
obtained after *i.v.* and oral administration to dogs (400 mg)




FIGURE 18

19/20

MHD Plasma levels
obtained after i.v. and oral administration to dogs (400 mg)




FIGURE 19

20 /20

Mean plasma MHD levels




FIGURE 20